Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Increasing evidence suggests that ionizing radiation therapy (RT) in combination with checkpoint immunotherapy is highly effective in treating a subset of cancers. To better understand the limited responses to this combination we analysed the genetic, microenvironmental, and immune factors in tumours derived from a transgenic breast cancer model. We identified two tumours with similar growth characteristics but different RT responses primarily due to an antitumour immune response. The combination of RT and checkpoint immunotherapy resulted in cures in the responsive but not the unresponsive tumours. Profiling the tumours revealed that the Axl receptor tyrosine kinase is overexpressed in the unresponsive tumours, and Axl knockout resulted in slower growth and increased radiosensitivity. These changes were associated with a CD8+ T-cell response, which was improved in combination with checkpoint immunotherapy. These results suggest a novel role for Axl in suppressing antigen presentation through MHCI, and enhancing cytokine release, which promotes a suppressive myeloid microenvironment.

Original publication

DOI

10.1038/ncomms13898

Type

Journal article

Journal

Nat Commun

Publication Date

23/12/2016

Volume

7

Keywords

Animals, Cell Line, Tumor, Cell Proliferation, Combined Modality Therapy, Cytokines, Histocompatibility Antigens Class I, Immunity, Immunosuppression, Immunotherapy, Mice, Inbred C57BL, Mice, Transgenic, Models, Biological, Molecular Targeted Therapy, Neoplasms, Proto-Oncogene Proteins, Radiation Tolerance, Receptor Protein-Tyrosine Kinases, Tumor Microenvironment